Key Highlights: Implications: Semaglutide generics could slash Novo Nordisk pricing by 70-80% in India’s $2.5B diabetes market (12% CAGR), capturing 25%+ share and pressuring chronic...
Key Highlights: Implications: StopBleed fills critical gap in India’s trauma response, handing emergency teams a game-changing tool that slashes preventable bleeding death...
Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
Key Highlights: Implications: IIL grabs first-mover advantage in niche viral vaccine space, dominating government tenders and regional immunization drives. Homegrown breakthrough smashes i...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
Key Highlights: Implications: Quality failures erode trust in high-volume generics, handing innovator brands a compliance advantage as hospitals pivot to verified suppliers. Tie...
